Dr. Craig A. Rohan, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Denver (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 329
Licensed in California since 2009, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Colorado School of Medicine, Denver
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license C53682 (first issued 2009; current) -
Pediatric Dermatology Physician
CA license C53682 (first issued 2009; current) -
Pediatrics Physician
CA license C53682 (first issued 2009; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Dermatologists of Southwestern Ohio, LLC (116 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 329
- Services billed
- 1,416
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 210 | 45 |
| Established patient office or other outpatient visit, 30-39 minutes | 182 | 108 |
| Established patient office or other outpatient visit, 20-29 minutes | 122 | 90 |
| Destruction of precancer skin growth, 1 growth | 64 | 54 |
| Established patient office or other outpatient visit, 10-19 minutes | 62 | 52 |
| New patient office or other outpatient visit, 30-44 minutes | 47 | 47 |
| New patient office or other outpatient visit, 45-59 minutes | 37 | 37 |
| Destruction of skin growth, 1-14 growths | 33 | 29 |
| Biopsy of related skin growth, first growth | 26 | 23 |
| New patient office or other outpatient visit, 15-29 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 17 payments worth $8,017 in total to this clinician.
| UCB SA | $7,014 |
|---|---|
| Novartis Pharmaceuticals Corporation | $1,003 |
| Compensation for services other than consulting (speaking, faculty) | $5,482 |
|---|---|
| Travel and Lodging | $2,010 |
| Food and Beverage | $525 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,295 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,170 |
| UCB SA Nov 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Toronto, Canada · in-kind | $705 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $565 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $446 |
| UCB SA Nov 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Toronto, Canada · in-kind | $331 |
| UCB SA Nov 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Toronto, Canada · in-kind | $330 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $198 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $169 |
| UCB SA Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $164 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Nov 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Toronto, Canada · in-kind | $705 |
| UCB SA Nov 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Toronto, Canada · in-kind | $331 |
| UCB SA Nov 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Toronto, Canada · in-kind | $330 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $446 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $198 |
| UCB SA Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $164 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,295 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,170 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $565 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $169 |
| UCB SA Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $120 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 10 companies. The companies reported $387,652 in research payments for these studies, mostly to the institutions running them.
- TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients wi…
Novartis Pharmaceuticals Corporation - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06136741 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized …
Janssen Research & Development, LLC - Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Organon Llc · Completed · NCT05172726 - A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Janssen Research & Development, LLC - A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Contro…
Amgen Inc. - M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
AbbVie Inc. - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 60 weeks of treatment with a withdrawal and retreatment period
Takeda Pharmaceuticals U.S.A., Inc. - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
AbbVie Inc. · Completed · NCT05969223
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.